We work closely with healthcare professionals to develop robotic solutions for treating vascular diseases such as heart attack and stroke.
Our first solution, R-One™¹, is designed to assist with PCI, the established standard treatment for coronary artery diseases.
¹ CE-mark pending
Doctor J. Fajadet, co-director of the cardiovascular disease department at the Clinique Pasteur in Toulouse (France), co-director of EuroPCR congress and Director of the EAPCI
R-One™ is a very intuitive tool. Getting started is very fast and simple. In particular, R-One™ allows instruments to be locked into place, so you never lose access to the lesion. It brings a significant revolution in our profession.
Doctor R. Sabatier, interventional cardiologist at Caen University Hospital (France)
Getting started is very easy and intuitive. The fact that the robot’s behavior is consistent and means the risk of human error can be reduced.
Professor A. Cribier, Former Chief of the cardiology department at the university hospital of Rouen, conceived and developed the TAVI
R-One™ represents a major step forward in interventional cardiology. This technology really impressed me and will give strong benefits to the healthcare system.
Doctor A. Cremonesi, head of the Villa Maria hospital cardiovascular department in Bologna (Italy) and active member of EuroPCR Board
This robotic platform is very impressive. It’s the future of our profession, not only for interventional cardiology, but also for peripheral vascular and neurovascular procedures.
From 29 January 2019 to 1 February 2019
From 21 May 2019 to 24 May 2019
Founded in 2009 by neuro-radiologist Dr Philippe Bencteux, Robocath designs and develops innovative robotic solutions for improving endovascular procedures. In particular, these procedures are carried out to treat cardiovascular diseases, including heart attacks, the leading cause of death worldwide¹. Selected by Forbes magazine as the fourth medical start-up in France, Robocath has around 20 employees.